Tango Therapeutics (NASDAQ:TNGX) added ~15% in the premarket on Thursday after the oncology-focused biotech announced an early-stage trial readout for its anticancer agent vopimetostat (TNG462) in ...
Tango dances away from preclinical work to extend cash runway, while Avalo lays out spending options
Biotech bank balances were again in focus Monday morning, with Tango Therapeutics cutting preclinical work to stretch its cash runway and Avalo Therapeutics outlining options for preserving its money.
Celebrating the rebellious tangos of Astor Piazzolla through dance and live music, choreographer and international tango ...
Tango Therapeutics Reports Q1 2025 Financial Results and Updates on TNG462 and Pipeline Developments
Data update from the TNG462 Phase 1/2 trial is expected in 2H 2025, which may provide significant insights into its efficacy, safety, and tolerability in treating pancreatic and lung cancer.
It’s a radio concert that’s so iconic, it was a key plot point in Disney’s 2003 remake of “Freaky Friday.” But with a new venue, new city and whole new vibe, it’s safe to say this isn’t your parents’ ...
(RTTNews) - Tango Therapeutics, Inc. (TNGX) fell 7.97% to $7.97, down $0.69, after announcing the pricing of an underwritten offering and concurrent PIPE expected to raise approximately $225 million.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback